Celentano D D, Vlahov D, Cohn S, Shadle V M, Obasanjo O, Moore R D
Department of Epidemiology, School of Hygiene and Public Health, The Johns Hopkins University, Baltimore, MD 21205, USA.
JAMA. 1998 Aug 12;280(6):544-6. doi: 10.1001/jama.280.6.544.
The US Public Health Service and the International AIDS Society-USA recently published recommendations for antiretroviral therapy (ART) for persons infected with human immunodeficiency virus (HIV); however, anecdotal evidence suggests that HIV-infected injection drug users (IDUs) may not be receiving optimal care as defined by the recommendations.
To assess ART use in HIV-infected IDUs.
A cross-sectional survey of self-reported ART use between July 1996 and June 1997 in IDUs.
A community-based clinic affiliated with Johns Hopkins University, Baltimore, Md.
A total of 404 HIV-infected IDUs with CD4+ cell counts less than 0.50 x 10(9)/L recruited into a longitudinal study in 1988 and 1989.
Self-reported ART use was assessed: no current therapy, monotherapy, or combination therapy with or without a protease inhibitor.
One half (199/404 [49%]) of patients reported no recent ART. A total of 14% (58/404) had monotherapy, 23% (90/404) were receiving combination therapy without a protease inhibitor, and 14% (57/404) had triple-combination therapy with a protease inhibitor. A multivariate analysis of factors associated with ART showed that care continuity and recent HIV-related outpatient visit (odds ratio [OR], 4.30; 95% confidence interval [CI], 2.36-7.81 and OR, 2.84; 95% CI, 1.66-4.88, respectively), CD4+ cell count of less than 0.20 x 10(9) (OR, 2.41; 95% CI, 1.51-3.84), no current drug use and being in drug treatment (OR, 2.16; 95% CI, 1.34-3.47; OR, 2.12; 95% CI, 1.23-3.66, respectively), and unemployment (OR, 2.31; 95% CI, 1.21-4.40) were associated with reporting ART use. In other analysis, less likely to receive protease inhibitors were current drug injectors (OR, 0.5; 95% CI, 0.3-1.0) and those recently incarcerated (OR, 0.2; 95% CI, 0.03-0.9), but patients with acquired immunodeficiency syndrome were more likely to receive protease inhibitors (OR, 2.0; 95% CI, 0.9-4.6). Protease inhibitor use doubled (P<.01) from July and December 1996 to January and June 1997 (7.7% and 14.8%, respectively).
Those IDUs infected with HIV who were not receiving ART tended to be active drug users without clinical disease who have less contact with health care providers. Although we do not have information on clinical judgment regarding treatment decisions or whether persons were prescribed therapy not taken, the proportion of subjects reporting receiving ART suggests that strategies for improving treatment in this population are indicated. Expanding simultaneous treatment services for HIV infection and substance abuse would enhance the response to these related epidemics.
美国公共卫生服务部和美国国际艾滋病协会最近发布了针对感染人类免疫缺陷病毒(HIV)者的抗逆转录病毒疗法(ART)建议;然而,轶事证据表明,感染HIV的注射吸毒者(IDU)可能未得到该建议所定义的最佳治疗。
评估感染HIV的IDU中抗逆转录病毒疗法的使用情况。
1996年7月至1997年6月期间对IDU中自我报告的抗逆转录病毒疗法使用情况进行的横断面调查。
马里兰州巴尔的摩市约翰·霍普金斯大学附属的一家社区诊所。
1988年和1989年招募到一项纵向研究中的404名CD4+细胞计数低于0.50×10⁹/L的感染HIV的IDU。
评估自我报告的抗逆转录病毒疗法使用情况:目前未治疗、单一疗法或含或不含蛋白酶抑制剂的联合疗法。
一半(199/404 [49%])的患者报告近期未接受抗逆转录病毒疗法。共有14%(58/404)接受单一疗法,23%(90/404)接受不含蛋白酶抑制剂的联合疗法,14%(57/404)接受含蛋白酶抑制剂的三联联合疗法。对与抗逆转录病毒疗法相关因素的多变量分析显示,护理连续性和近期与HIV相关的门诊就诊(优势比[OR],4.30;95%置信区间[CI],2.36 - 7.81和OR,2.84;95% CI,1.66 - 4.88)、CD4+细胞计数低于0.20×10⁹(OR,2.41;95% CI,1.51 - 3.84)、目前未吸毒且正在接受戒毒治疗(OR,2.16;95% CI,1.34 - 3.47;OR,2.12;95% CI,1.23 - 3.66)以及失业(OR,2.31;95% CI,1.21 - 4.40)与报告使用抗逆转录病毒疗法相关。在其他分析中,目前的药物注射者(OR,0.5;95% CI,0.3 - 1.0)和近期被监禁者(OR,0.2;95% CI,0.03 - 0.9)接受蛋白酶抑制剂的可能性较小,但获得性免疫缺陷综合征患者接受蛋白酶抑制剂的可能性较大(OR,2.0;95% CI,0.9 - 4.6)。1996年7月至12月至1997年1月至6月期间,蛋白酶抑制剂的使用增加了一倍(P<0.01)(分别为7.7%和14.8%)。
那些未接受抗逆转录病毒疗法的感染HIV的IDU往往是有活跃吸毒行为且无临床疾病的人,他们与医疗服务提供者的接触较少。尽管我们没有关于治疗决策的临床判断或是否有人被开具了未服用的治疗药物的信息,但报告接受抗逆转录病毒疗法的受试者比例表明,需要制定改善该人群治疗的策略。扩大针对HIV感染和药物滥用的同步治疗服务将加强对这些相关流行病的应对。